Sino Biological Inc. Class A

Sino Biological Inc. Class A

SSZSE:301047
89.24
CNY
-2.68
(-2.92%)
1.47EPS
108.00P/E
19.34BMarket Cap
Apr 19Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.05
1.08
1.4
16.47
17.03
5.04
5
4.8
5.75
6.51
Basic EPS, GAAP
0.14
0.28
0.28
11.64
12.71
2.66
2.01
0.95
1.21
1.47
Free Cash Flow per Basic Share
0.09
0.07
0.06
11.09
10.49
0.82
-5.58
0.34
0.37
- -
Dividend per Share
- -
- -
- -
- -
- -
5.97
2
2
5
1
Book Value per Share
0.41
0.82
1.55
13.4
52.26
49.3
49.28
47.46
43.69
42.47
Tangible Book Value per Share
0.41
0.82
1.54
13.4
52.26
49.29
49.27
44.8
41.05
40.05
Basic Weighted Avg Shares
97
129
129
97
57
114
129
128
122
122
Sales/Revenue/Turnover
101
139
181
1,596
965
575
646
614
700
792
Operating Margin (%)
19.23
26.77
100
85.05
80.71
39.6
25.35
8.92
14.93
19.76
Depreciation Expense
3
6
44
11
26
38
70
91
91
- -
Net Income, GAAP
13
36
36
1,128
720
303
260
122
148
179
Effective Tax Rate (%)
2.3
- -
7.28
14.13
14.84
11.55
9.66
13.73
17.71
16.71
Profit Margin (%)
12.91
26.11
20.14
70.64
74.59
52.72
40.24
19.87
21.12
22.61
Working Capital
5
39
84
1,189
6,620
5,899
4,933
4,010
3,365
3,130
LT Debt
- -
- -
- -
16
27
51
62
45
31
31
Total Equity
40
79
150
1,299
6,752
6,369
6,367
5,773
5,315
5,166
Return on Invested Capital (%)
- -
- -
33.76
147.58
17.5
4.58
4.04
1.99
2.64
3.25
Return on Capital (%)
- -
- -
31.82
153.23
17.77
4.61
4.09
2.04
2.68
3.29
Return on Common Equity (%)
- -
61.03
31.82
155.7
17.89
4.62
4.08
2.01
2.66
3.29

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
15
11
10
LT Borrowings
- -
- -
- -
LT Finance Leases
31
29
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
122
122
122
Market Capitalization
8,626
7,853
19,340

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
3,551
3,429
3,281
Cash, Cash Equivalents & STI
3,255
3,128
2,963
Accounts Receivable, Net
182
193
208
Inventories
80
76
71
Total Current Liabilities
133
135
151
Payables & Accruals
- -
- -
- -
ST Debt
15
11
10
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
79.39%
-7.94%
Free Cash Flow
- -
-220.84%
3.1%
Net Income, GAAP
- -
-28.03%
21.17%
Sales/Revenue/Turnover
- -
-11.71%
14%
Total Cash Common Dividend
- -
- -
138.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
152
153
159
149
614
2025
155
169
- -
188
700
2026
183
209
211
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.34
0.21
0.23
0.19
0.95
2025
0.19
0.37
- -
0.31
1.21
2026
0.26
0.44
0.46
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2
2025
- -
- -
- -
- -
5
2026
- -
- -
1
- -
- -

Company Description

CEO
Jie Zhang
Full Time Employees
1,069
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Beijing China
IPO Date
Aug 16, 2021
Business
Sino Biological, Inc. is a global biotechnology company that specializes in the research, development, manufacture, and commercialization of life science research reagents and custom contract research services for biomedical research, therapeutic discovery, and in vitro diagnostics. Founded in 2007 and headquartered in Beijing, China, the company operates primarily across two business segments: biological reagents and technical contract services. Its core product portfolio comprises recombinant proteins, including cytokines, growth factors, viral antigens, immune checkpoint targets, receptor proteins, and enzymes; research-grade and diagnostic antibodies, including monoclonal antibodies, polyclonal antibodies, recombinant rabbit monoclonal antibodies, neutralizing antibodies, and matched antibody pairs; enzyme-linked immunosorbent assay kits and quantitative assay reagents; and molecular biology tools, including cDNA clones, transfection reagents, and cell culture media formulations. In addition, the company provides comprehensive contract research organization services, including custom recombinant protein expression and purification across mammalian, insect, and microbial host systems; custom hybridoma and recombinant antibody generation; antibody humanization and characterization; epitope binning and binding kinetics analysis; bioanalytical assay development; and pharmacokinetic and anti-drug antibody assay support. Sino Biological serves pharmaceutical and biotechnology companies, academic institutions, diagnostic manufacturers, and contract research organizations worldwide. The company maintains operational facilities, research laboratories, and distribution hubs across China, the United States, Germany, and Japan, distributing products to clients in more than 90 countries. In recent corporate developments, Sino Biological has executed strategic growth initiatives, including the acquisition of Canadian life science firm SignalChem Lifesciences to expand its active kinase, enzyme, and bioreagent product portfolios. The company has also strengthened its international footprint through the establishment of its Center for Bioprocessing and new innovation facilities in the United States, launched high-throughput artificial intelligence-assisted antibody engineering platforms, and formed strategic alliances with life science technology providers to broaden its global diagnostic and therapeutic research offerings.